September 24, 2021 -- Gamma Biosciences has made an investment in bioprocessing firm Nirrin Technologies. Terms of the investment were not disclosed.
Gamma will provide support to Nirrin for helping expand customer engagement with the developer and manufacturers of cell and gene therapies, biologics, and vaccines, the company said.
Nirrin's bioprocessing platform uses near-infrared spectroscopy and back-end data processing for applications such as real-time glucose monitoring, cell density in-line measurements, and protein concentration and aggregation, according to Gamma Biosciences.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
